If such a trial is in fact being planned, it must be either: a) a trial for the ex-US market; or b) a bioequivalence trial (as opposed to a safety and efficacy trial). Wheeler addressed a question regarding a potential trial at the very end of his Cowen Presentation. http://www.wsw.com/webcast/cowen3/mnta/